AbbVie Stock News

The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in emerging markets, and increased demand for personalized medicine. Despite challenges like high costs and competition, the market, led by AbbVie Inc. (ImmunoGen), presents vast opportunities, particul...

Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment stayed cautious, contributing to investor uncertainty. May's investments added $111 in annual dividends, keeping me on track with my goal of $100+ monthly income growth and a 7.4% yield on cost.

Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.

US stocks could see pressure this week after Iran struck US bases in Qatar in retaliation for President Trump's airstrike on Tehran's nuclear facilities. Amidst the geopolitical backdrop that seems to be worsening by the day, investors could find some stability in dividend stocks as they are historically viewed as a remarkable hedge against volatility.

Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term growth drivers, resulting in a dislocation between price and value.

NORTH CHICAGO, Ill. , June 20, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage trial.

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month 1 Atogepant met the primary endpoint of fewer treatment discontinuations attributed to adverse events versus topiramate, a...